Orchestra BioMed Holdings Inc. Ordinary Shares (OBIO)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power, honest accounting, and a margin of safety. Orchestra BioMed is not that today. It is an 86-employee clinical-stage biomedical company whose candidates target hypertension, atherosclerotic artery disease, and heart failure. At the 2026-10-13 close of $5.72, the market values it at $343.8M. FairStock’s calculations show a negative P/E of -6.81, a P/B of 17.87, ROE of -397.30%, ROCE of -45.73%, and D/E of 2.41. Those are not the marks of a mature compounder. Revenue is erratic: filed FY2025 (period ended 2025-12-31) revenue was $33.5M with a net loss of $52.7M, while FY2024 (period ended 2024-12-31) revenue was $2.6M with a net loss of $61.0M, and FY2023 (period ended 2023-12-31) revenue was $2.8M with a net loss of $49.1M. More recently, in fiscal Q2 2026 (quarter ended 2026-06-30), revenue was just $88,000 and net loss was $23.8M; in fiscal Q1 2026 (quarter ended 2026-03-31), revenue was $110,000 and net loss was $20.7M. Trailing free cash flow is -$59.1M, a FairStock FCF yield of -17.2%. FairStock’s Piotroski F-Score is 4/9 and Altman Z-Score is -2.41, suggesting weak financial signals. The Lynch category is none because it has lost money in each of the last four years. Any competitive moat would depend on clinical and regulatory success, not proven commercial scale. I would want proof of durable revenue, controlled cash burn, and a much lower price before calling this a value opportunity. Until then, it is a speculative bet on future medicine, not a Graham-style bargain.

In plain English: Orchestra BioMed is a small healthcare company developing treatments for high blood pressure, artery disease, and heart failure. It is still testing its products and has almost no sales right now, and it loses millions of dollars each quarter. The stock looks expensive compared with the current business because there are no profits and only tiny revenue to support the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer